U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07016490) titled 'A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors' on May 28.
Brief Summary: This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and anti-tumor activity of SSGJ-709 as a single agent in patients with advanced malignancies.
Study Start Date: June 06
Study Type: INTERVENTIONAL
Condition:
Advanced Malignant Tumors
Intervention:
DRUG: SSGJ-709
A bispecific antibody targeting PD-1 and LAG-3.
Recruitment Status: RECRUITING
Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
Published by HT Digital Content Services with permission from Health Daily Digest....